GSK's Recombinant RSV Vaccine Arexvy Demonstrates Protection Across Three Respiratory Seasons

▎Armstrong

On October 8, 2024, GSK announced the latest long-term follow-up data for the recombinant RSV vaccine Arexvy, indicating protection across three epidemic seasons.

The protection rates against RSV-LRTD for the first, second, and third epidemic seasons were 82.6%, 56.1%, and 48.0%, respectively, with a cumulative protection rate of 62.9%. For severe LRTD symptoms, the protection...The1, 2, 3 PopularThe protective rates for the seasons were 94.1%, 64.2%, and 43.3%, respectively, with a cumulative protective rate of 67.4%. For high-risk populations,The1, 2, 3 PopularThe protection rates for the seasons were 94.6%, 51.5%, and 57.8%, respectively, with a cumulative protection rate of 64.7%.

Summary

It can be seen that although Arexvy can provide protection for three epidemic seasons, the protection rate decreases rapidly, and by the third year, the protection rates for RSV-LRTD and severe LRTD drop below 50%. Long-term follow-up data will help to ultimately determine the vaccination schedule for RSV vaccines, which will most likely require vaccination every few years.